Stem Cell Worx Competitors

Pluristem Therapeutics Inc. (NasdaqCM: PSTI, TASE: PSTI/PLTR) is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation. Pluristem’s PLacental eXpanded (PLX) cells are placenta-derived, mesenchymal-like adherent stromal cells that are designed to be administered to patients without the need for tissue or genetic matching. These cells release soluble biomolecules, such as cytokines, chemokines and growth factors, which act in a paracrine or endocrine manner to facilitate healing of damaged tissues by stimulating the body’s own regenerative mechanisms. The Company’s proprietary, 3D expansion technology can be used to grow PLX cells in mass quantities with batch-to-batch consistency at Pluristem’s FDA, EMA and PMDA-approved, state-of-the art manufacturing facility. Pluristem’s first product candidate is PLX-PAD, a cell therapy product for the treatment of tissues that have been damaged by ischemia, muscle trauma, or inflammation. Pluristem’s second cell therapy product in development, PLX-R18, is designed to treat hematological conditions including ARS, insufficient hematopoietic recovery following hematopoietic cell transplantation (HCT) , certain cancers or cancer treatments

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and exosome/extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and exosome production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type II Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under one year. RoosterBio is driven by our client's success and creating a world where safe and effective advanced therapies are rapidly developed and widely available on a global scale.